EHA 2021 | Improved survival of myelofibrosis patients receiving ruxolitinib post allo-HSCT
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discussess the long-term safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients with myelofibrosis. Data from 12 patients was analyzed in a retrospective study, which reported that patients who received ruxolitinib following alloHCT did not suffer from treatment-related mortality, and that the two-year disease-free survival for patients who received ruxolitinib following alloHCT was 75%, compared to 14.3% for patients who did not receive ruxolitinib. Two-year overall survival was significantly improved in patients who received ruxolitinib following alloHCT. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Eleni Gavriilaki, MD, PhD, has participated in consultancy work with Alexion and Omeros Corporation.
